A broad range of policy-relevant clinical questions are amenable to research, ranging from comparisons of the implementation approaches for value based care, to understanding comparative differences in a treatment’s measured efficacy in a clinical trial compared to its effectiveness in clinical practice.

Members of the Center engage in research looking at such comparisons using an array of methods including systematic reviews, observational data analyses, and simulation modeling. A high profile example of this type of research within the Center led to MSK rejecting the colorectal cancer drug ziv-aflibercept (Zaltrap^®) from its formulary, after determining it was no better than a drug that cost half its price. This action was covered by The New York Times and on 60 Minutes.